Thyroid RFA 101: Quality of Life Improved after RFA Treatment of Large Benign Thyroid Nodules

Thyroid RFA 101: Quality of Life Improved after RFA Treatment of Large Benign Thyroid Nodules

Thyroid RFA 101: Quality of Life Improved after RFA Treatment of  Large Benign Thyroid Nodules

Thyroid RFA 101: Quality of Life both physically and mentally Improved after RFA Treatment of Large Benign Thyroid Nodules.

 HEALTH-RELATED QUALITY OF LIFE AFTER PERCUTANEOUS RADIOFREQUENCY ABLATION OF COLD, SOLID, BENIGN THYROID NODULES: A 2-YEAR FOLLOW-UP STUDY IN 40 PATIENTS.
e9b4e2_3f04398f43224ac6a3255e69806b6894mv2
e9b4e2_89fc7eb6e2444e6ba931227ce049eb9cmv2
 Endocr Pract. 2015 Aug;21(8):887-96.

Abstract

OBJECTIVE:

We studied the impact of radiofrequency ablation (RFA) on health-related quality of life (HRQL) in patients with benign thyroid nodules (TN) in a 2-year follow-up.

METHODS:

Forty patients (35 women and 5 men; age, 54.9 ± 14.3 years) with cold thyroid solitary nodules or a dominant nodule within a normofunctioning multi-nodular goiter (volume range, 6.5 to 90.0 mL) underwent RFA of thyroid nodular tissue under ultrasound real-time assistance.

RESULTS:

Data are mean and standard deviation. Energy delivered was 37,154 ± 18,092 joules, with an output power of 37.4 ± 8.8 watts. Two years after RFA, nodule volume decreased from 30.0 ± 18.2 mL to 7.9 ± 9.8 mL (-80.1 ± 16.1% of initial volume; P<.0001). Thyroid-stimulating hormone, free triiodothyronine, and free thyroxine levels remained stable. Symptom score measured on a 0- to 10-cm visual analogue scale (VAS) declined from 5.6 ± 3.1 cm to 1.9 ± 1.3 cm (P<.0001). Cosmetic score (VAS 0-10 cm) declined from 5.7 ± 3.2 cm to 1.9 ± 1.5 cm (P<.0001). Two patients became anti-thyroglobulin antibody-positive. Physical Component Summary (PCS)-12 improved from 50.4 ± 8.9 to 54.5 ± 5.3, and the Mental Component Summary (MCS)-12 improved from 36.0 ± 13.3 to 50.3 ± 6.3 (P<.0001 for both score changes).

CONCLUSION:

Our 2-year follow-up study confirms that RFA of benign TNs is effective in reducing nodular volume and compressive and cosmetic symptoms, without causing thyroid dysfunction or life-threatening complications. Our data indicate that the achievement of these secondary endpoints is associated with HRQL improvement, measured both as PCS and MCS.

Comments: Call Matt at my center for details on my evaluation for candidacy for RFA in Italy or Korea with Dr Valcavi or Dr.Baek.

310-393-8860 or email thyroid.manager@protonmail.com

Add Your Comment

Contact Info
1328 16th Street, Santa Monica, CA 90404
Monday – Friday
9:00 AM to 5:00 PM
(310) 393-8860